메뉴 건너뛰기




Volumn 104, Issue 3, 2015, Pages 930-941

The current status and prospects of antibody engineering for therapeutic use: Focus on glycoengineering technology

Author keywords

Biotechnology; Cancer; Conjugation; Glycosylation; Immunology; Immunotherapy; Targeted drug delivery; Therapeutic antibody

Indexed keywords

BISPECIFIC ANTIBODY; DEFUCOSYLATED ANTIBODY; DRUG ANTIBODY; FC RECEPTOR; FUCOSE; GLYCOENGINEERED ANTIBODY; MEMBRANE ANTIGEN; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OLIGOSACCHARIDE; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE;

EID: 84922807192     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24316     Document Type: Review
Times cited : (53)

References (130)
  • 1
    • 0346098179 scopus 로고    scopus 로고
    • History of antibody therapy for non-Hodgkin's lymphoma
    • Forero A, Lobuglio AF. 2003. History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol 30:1-5.
    • (2003) Semin Oncol , vol.30 , pp. 1-5
    • Forero, A.1    Lobuglio, A.F.2
  • 2
    • 0346328325 scopus 로고    scopus 로고
    • Rituximab (Rituxan/MabThera): The first decade (1993-2003)
    • Grillo-Lopez AJ. 2003. Rituximab (Rituxan/MabThera): The first decade (1993-2003). Expert Rev Anticancer Ther 3:767-769.
    • (2003) Expert Rev Anticancer Ther , vol.3 , pp. 767-769
    • Grillo-Lopez, A.J.1
  • 3
    • 0242721899 scopus 로고    scopus 로고
    • Clinical experience with trastuzumab (herceptin)
    • Vogel CL, Franco SX. 2003. Clinical experience with trastuzumab (herceptin). Breast J 9:452-462.
    • (2003) Breast J , vol.9 , pp. 452-462
    • Vogel, C.L.1    Franco, S.X.2
  • 4
    • 0036214044 scopus 로고    scopus 로고
    • The ErbB receptor family: A therapeutic target for cancer
    • de Bono JS, Rowinsky EK. 2002. The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 8:S19-S26.
    • (2002) Trends Mol Med , vol.8 , pp. S19-S26
    • De Bono, J.S.1    Rowinsky, E.K.2
  • 5
    • 2442590862 scopus 로고    scopus 로고
    • New drugs for rheumatoid arthritis
    • Olsen NJ, Stein CM. 2004. New drugs for rheumatoid arthritis. N Engl J Med 350:2167-2179.
    • (2004) N Engl J Med , vol.350 , pp. 2167-2179
    • Olsen, N.J.1    Stein, C.M.2
  • 6
    • 0029891262 scopus 로고    scopus 로고
    • The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor
    • Junghans RP, Anderson CL. 1996. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 93:5512-5516.
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 5512-5516
    • Junghans, R.P.1    Anderson, C.L.2
  • 8
    • 0001871568 scopus 로고
    • Therapeutic applications of monoclonal antibodies for human disease
    • Birch JR, Lennox ES New York: Wiley-Liss
    • Scheinberg DA, Chapman PB. 1995. Therapeutic applications of monoclonal antibodies for human disease. In Monoclonal antibodies: Principles and applications; Birch JR, Lennox ES, Eds. New York: Wiley-Liss, pp 45-105.
    • (1995) Monoclonal Antibodies: Principles and Applications , pp. 45-105
    • Scheinberg, D.A.1    Chapman, P.B.2
  • 10
    • 0017102773 scopus 로고
    • Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement
    • Schumaker VN, Calcott MA, Spiegelberg HL,Müller-Eberhard HJ.1976. Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry 15:5175-5181.
    • (1976) Biochemistry , vol.15 , pp. 5175-5181
    • Schumaker, V.N.1    Calcott, M.A.2    Spiegelberg, H.L.3    Müller-Eberhard, H.J.4
  • 12
    • 34548229364 scopus 로고    scopus 로고
    • FcRn: The neonatal Fc receptor comes of age
    • Roopenian DC, Shreeram A. 2007. FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725.
    • (2007) Nat Rev Immunol , vol.7 , pp. 715-725
    • Roopenian, D.C.1    Shreeram, A.2
  • 13
    • 0031014785 scopus 로고    scopus 로고
    • IgG effector mechanisms
    • Clark MR. 1997. IgG effector mechanisms. Chem Immunol 65:88-110.
    • (1997) Chem Immunol , vol.65 , pp. 88-110
    • Clark, M.R.1
  • 14
    • 0028970836 scopus 로고
    • The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding
    • Morgan A, Jones ND, Nesbitt AM, Chaplin L, Bodmer MW, Emtage JS. 1995. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding. Immunology 86:319-324.
    • (1995) Immunology , vol.86 , pp. 319-324
    • Morgan, A.1    Jones, N.D.2    Nesbitt, A.M.3    Chaplin, L.4    Bodmer, M.W.5    Emtage, J.S.6
  • 15
    • 0037013743 scopus 로고    scopus 로고
    • Interaction sites on human IgG-Fc for FcgammaR: Current models
    • Jefferis R, Lund J. 2002. Interaction sites on human IgG-Fc for FcgammaR: Current models. Immunol Lett 82:57-65.
    • (2002) Immunol Lett , vol.82 , pp. 57-65
    • Jefferis, R.1    Lund, J.2
  • 16
    • 0024544730 scopus 로고
    • Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors
    • Walker MR, Lund J, Thompson KM, Jefferis R. 1989. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259:347-353.
    • (1989) Biochem J , vol.259 , pp. 347-353
    • Walker, M.R.1    Lund, J.2    Thompson, K.M.3    Jefferis, R.4
  • 17
    • 0024438061 scopus 로고
    • Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region
    • Tao MH, Morrison SL. 1989. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 143:2595-2601.
    • (1989) J Immunol , vol.143 , pp. 2595-2601
    • Tao, M.H.1    Morrison, S.L.2
  • 18
    • 0037474543 scopus 로고    scopus 로고
    • Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity
    • Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. 2003.Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 325:979-989.
    • (2003) J Mol Biol , vol.325 , pp. 979-989
    • Krapp, S.1    Mimura, Y.2    Jefferis, R.3    Huber, R.4    Sondermann, P.5
  • 19
    • 0024544730 scopus 로고
    • Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors
    • Walker MR, Lund J, Thompson KM, Jefferis R. 1989. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fc gamma RI and/or Fc gamma RII receptors. Biochem J 259:347-353.
    • (1989) Biochem J , vol.259 , pp. 347-353
    • Walker, M.R.1    Lund, J.2    Thompson, K.M.3    Jefferis, R.4
  • 20
    • 0017152608 scopus 로고
    • Crystallographic structure studies of an IgG molecule and an Fc fragment
    • Huber R, Deisenhofer J, Colman PM, Matsushima M, Palm W.1976. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 264:415-420.
    • (1976) Nature , vol.264 , pp. 415-420
    • Huber, R.1    Deisenhofer, J.2    Colman, P.M.3    Matsushima, M.4    Palm, W.5
  • 21
  • 22
    • 0032488888 scopus 로고    scopus 로고
    • Crystallographic structure of an intact IgG1 monoclonal antibody
    • Harris LJ, Skaletsky E, McPherson A. 1998. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 275:861-872.
    • (1998) J Mol Biol , vol.275 , pp. 861-872
    • Harris, L.J.1    Skaletsky, E.2    McPherson, A.3
  • 23
    • 0019934863 scopus 로고
    • Structural and numerical variations of the carbohydrate moiety of immunoglobulin G
    • Mizuochi T, Taniguchi T, Shimizu A, Kobata A. 1982. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 129:2016-2020.
    • (1982) J Immunol , vol.129 , pp. 2016-2020
    • Mizuochi, T.1    Taniguchi, T.2    Shimizu, A.3    Kobata, A.4
  • 24
    • 0023243297 scopus 로고
    • Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns
    • Harada H, Kamei M, Tokumoto Y, Yui S, Koyama F, Kochibe N, Endo T, Kobata A. 1987. Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. Anal Biochem 164:374-381.
    • (1987) Anal Biochem , vol.164 , pp. 374-381
    • Harada, H.1    Kamei, M.2    Tokumoto, Y.3    Yui, S.4    Koyama, F.5    Kochibe, N.6    Endo, T.7    Kobata, A.8
  • 26
    • 33751253486 scopus 로고    scopus 로고
    • Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality
    • Scallon BJ, Tam SH, McCarthy SG, Cai AN, Raju TS. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44:1524-1534.
    • (2007) Mol Immunol , vol.44 , pp. 1524-1534
    • Scallon, B.J.1    Tam, S.H.2    McCarthy, S.G.3    Cai, A.N.4    Raju, T.S.5
  • 27
    • 0028670916 scopus 로고
    • Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity
    • Kumpel BM, Rademacher TW, Rook GA, Williams PJ, Wilson IB.1994. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum Antibodies Hybridomas 5:143-151.
    • (1994) Hum Antibodies Hybridomas , vol.5 , pp. 143-151
    • Kumpel, B.M.1    Rademacher, T.W.2    Rook, G.A.3    Williams, P.J.4    Wilson, I.B.5
  • 28
    • 0033044588 scopus 로고    scopus 로고
    • Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
    • Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. 1999.Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17:176-180.
    • (1999) Nat Biotechnol , vol.17 , pp. 176-180
    • Umãa, P.1    Jean-Mairet, J.2    Moudry, R.3    Amstutz, H.4    Bailey, J.E.5
  • 29
    • 84863440630 scopus 로고    scopus 로고
    • Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans
    • Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan JP, Bayer R. 2012. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 24:475-487.
    • (2012) MAbs , vol.24 , pp. 475-487
    • Yu, M.1    Brown, D.2    Reed, C.3    Chung, S.4    Lutman, J.5    Stefanich, E.6    Wong, A.7    Stephan, J.P.8    Bayer, R.9
  • 30
  • 31
    • 48549090941 scopus 로고    scopus 로고
    • Terminal sugars of Fc glycans influence antibody effector functions of IgGs
    • Raju TS. 2008. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20:471-478.
    • (2008) Curr Opin Immunol , vol.20 , pp. 471-478
    • Raju, T.S.1
  • 32
    • 38549176118 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
    • Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. 2008. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 117:244-279.
    • (2008) Pharmacol Ther , vol.117 , pp. 244-279
    • Tracey, D.1    Klareskog, L.2    Sasso, E.H.3    Salfeld, J.G.4    Tak, P.P.5
  • 33
    • 33845961014 scopus 로고    scopus 로고
    • Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
    • Shih T, Lindley C. 2006. Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779-1802.
    • (2006) Clin Ther , vol.28 , pp. 1779-1802
    • Shih, T.1    Lindley, C.2
  • 35
    • 0036464719 scopus 로고    scopus 로고
    • Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    • Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758.
    • (2002) Blood , vol.99 , pp. 754-758
    • Cartron, G.1    Dacheux, L.2    Salles, G.3    Solal-Celigny, P.4    Bardos, P.5    Colombat, P.6    Watier, H.7
  • 36
    • 3042743884 scopus 로고    scopus 로고
    • Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship
    • Dall'Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. 2004. Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64:4664-4669.
    • (2004) Cancer Res , vol.64 , pp. 4664-4669
    • Dall'Ozzo, S.1    Tartas, S.2    Paintaud, G.3    Cartron, G.4    Colombat, P.5    Bardos, P.6    Watier, H.7    Thibault, G.8
  • 37
    • 0037289807 scopus 로고    scopus 로고
    • The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    • Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ. 2003. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455-459.
    • (2003) Arthritis Rheum , vol.48 , pp. 455-459
    • Anolik, J.H.1    Campbell, D.2    Felgar, R.E.3    Young, F.4    Sanz, I.5    Rosenblatt, J.6    Looney, R.J.7
  • 38
    • 0642373290 scopus 로고    scopus 로고
    • Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
    • Weng WK, Levy R. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947.
    • (2003) J Clin Oncol , vol.21 , pp. 3940-3947
    • Weng, W.K.1    Levy, R.2
  • 42
    • 0019934863 scopus 로고
    • Structural and numerical variations of the carbohydrate moiety of immunoglobulin G
    • Mizuochi T, Taniguchi T, Shimizu A, Kobata A. 1982. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 129:2016-2020.
    • (1982) J Immunol , vol.129 , pp. 2016-2020
    • Mizuochi, T.1    Taniguchi, T.2    Shimizu, A.3    Kobata, A.4
  • 43
    • 0023243297 scopus 로고
    • Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns
    • Harada H, Kamei M, Tokumoto Y, Yui S, Koyama F, Kochibe N, Endo T, Kobata A. 1987. Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. Anal Biochem 164:374-381.
    • (1987) Anal Biochem , vol.164 , pp. 374-381
    • Harada, H.1    Kamei, M.2    Tokumoto, Y.3    Yui, S.4    Koyama, F.5    Kochibe, N.6    Endo, T.7    Kobata, A.8
  • 44
    • 0037178791 scopus 로고    scopus 로고
    • Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity
    • Shields RL, Lai J,Keck R, O'Connell LY, Hong K, Meng YG,Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity. J Biol Chem 277:26733-26740.
    • (2002) J Biol Chem , vol.277 , pp. 26733-26740
    • Shields, R.L.1    Lai, J.2    Keck, R.3    O'Connell, L.Y.4    Hong, K.5    Meng, Y.G.6    Weikert, S.H.7    Presta, L.G.8
  • 45
    • 0037474276 scopus 로고    scopus 로고
    • The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity
    • Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 278:3466-3473.
    • (2003) J Biol Chem , vol.278 , pp. 3466-3473
    • Shinkawa, T.1    Nakamura, K.2    Yamane, N.3    Shoji-Hosaka, E.4    Kanda, Y.5    Sakurada, M.6    Uchida, K.7    Anazawa, H.8    Satoh, M.9    Yamasaki, M.10    Hanai, N.11    Shitara, K.12
  • 46
    • 12144289636 scopus 로고    scopus 로고
    • Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma
    • Niwa R, Shoji-Hosaka E, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K. 2004. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 64:2127-2133.
    • (2004) Cancer Res , vol.64 , pp. 2127-2133
    • Niwa, R.1    Shoji-Hosaka, E.2    Sakurada, M.3    Shinkawa, T.4    Uchida, K.5    Nakamura, K.6    Matsushima, K.7    Ueda, R.8    Hanai, N.9    Shitara, K.10
  • 48
    • 33646070900 scopus 로고    scopus 로고
    • Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous $ 1, 4-N-acetylglucosaminyltransferase III and Golgi a-mannosidase II
    • Ferrara C, Brunker P, Suter T, Moser S, Puntener U, Umana P.2006. Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co-expression of heterologous $ 1, 4-N-acetylglucosaminyltransferase III and Golgi a-mannosidase II. Biotechnol Bioeng 93:851-861.
    • (2006) Biotechnol Bioeng , vol.93 , pp. 851-861
    • Ferrara, C.1    Brunker, P.2    Suter, T.3    Moser, S.4    Puntener, U.5    Umana, P.6
  • 53
  • 56
    • 16844381436 scopus 로고    scopus 로고
    • Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibodydependent cellular cytotoxicity induction at lower antigen density
    • Niwa R, Sakurada M,Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K. 2005. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibodydependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 11:2327-2336.
    • (2005) Clin Cancer Res , vol.11 , pp. 2327-2336
    • Niwa, R.1    Sakurada, M.2    Kobayashi, Y.3    Uehara, A.4    Matsushima, K.5    Ueda, R.6    Nakamura, K.7    Shitara, K.8
  • 57
    • 3042606229 scopus 로고    scopus 로고
    • Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: Possible inhibitory effect of IgG
    • Vugmeyster Y, Howell K. 2004. Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: Possible inhibitory effect of IgG. Int Immunopharmacol 24:1117-1124.
    • (2004) Int Immunopharmacol , vol.24 , pp. 1117-1124
    • Vugmeyster, Y.1    Howell, K.2
  • 58
    • 30344434022 scopus 로고    scopus 로고
    • High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibodydependent cellular cytotoxicity by excess endogenous immunoglobulin G
    • Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS. 2006. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibodydependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 43:1183-1193.
    • (2006) Mol Immunol , vol.43 , pp. 1183-1193
    • Preithner, S.1    Elm, S.2    Lippold, S.3    Locher, M.4    Wolf, A.5    Da Silva, A.J.6    Baeuerle, P.A.7    Prang, N.S.8
  • 59
    • 33646740982 scopus 로고    scopus 로고
    • Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa
    • Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M. 2006. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 12:2879-2887.
    • (2006) Clin Cancer Res , vol.12 , pp. 2879-2887
    • Iida, S.1    Misaka, H.2    Inoue, M.3    Shibata, M.4    Nakano, R.5    Yamane-Ohnuki, N.6    Wakitani, M.7    Yano, K.8    Shitara, K.9    Satoh, M.10
  • 60
    • 59749104215 scopus 로고    scopus 로고
    • Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils
    • Shibata-Koyama M, Iida S, Misaka H, Mori K, Yano K, Shitara K, Satoh M. 2009. Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 37:309-321.
    • (2009) Exp Hematol , vol.37 , pp. 309-321
    • Shibata-Koyama, M.1    Iida, S.2    Misaka, H.3    Mori, K.4    Yano, K.5    Shitara, K.6    Satoh, M.7
  • 62
    • 0030806221 scopus 로고    scopus 로고
    • Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells
    • Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES. 1997. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA 94:7509-7514.
    • (1997) Proc Natl Acad Sci USA , vol.94 , pp. 7509-7514
    • Ghetie, M.A.1    Podar, E.M.2    Ilgen, A.3    Gordon, B.E.4    Uhr, J.W.5    Vitetta, E.S.6
  • 63
    • 0035282930 scopus 로고    scopus 로고
    • Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin
    • Ghetie MA, Bright H, Vitetta ES. 2001. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 97:1392-1398.
    • (2001) Blood , vol.97 , pp. 1392-1398
    • Ghetie, M.A.1    Bright, H.2    Vitetta, E.S.3
  • 64
    • 77950074334 scopus 로고    scopus 로고
    • Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils
    • Nakagawa T, Natsume A, Satoh M, Niwa R. 2010. Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils. Leuk Res 34:666-671.
    • (2010) Leuk Res , vol.34 , pp. 666-671
    • Nakagawa, T.1    Natsume, A.2    Satoh, M.3    Niwa, R.4
  • 65
    • 0037033448 scopus 로고    scopus 로고
    • Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells
    • Dhodapkar KM, Krasovsky J,Williamson B, Dhodapkar MV. 2002.Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125-133.
    • (2002) J Exp Med , vol.195 , pp. 125-133
    • Dhodapkar, K.M.1    Krasovsky, J.2    Williamson, B.3    Dhodapkar, M.V.4
  • 67
    • 77956545725 scopus 로고    scopus 로고
    • Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
    • Abès R, Gélizé E, Fridman WH, Teillaud JL. 2010. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:926-934.
    • (2010) Blood , vol.116 , pp. 926-934
    • Abès, R.1    Gélizé, E.2    Fridman, W.H.3    Teillaud, J.L.4
  • 69
    • 78049427830 scopus 로고    scopus 로고
    • Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape
    • Ferris RL, Jaffee EM, Ferrone S. 2010. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. J Clin Oncol 28:4390-4399.
    • (2010) J Clin Oncol , vol.28 , pp. 4390-4399
    • Ferris, R.L.1    Jaffee, E.M.2    Ferrone, S.3
  • 70
    • 0029946383 scopus 로고    scopus 로고
    • 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization
    • Ridgway JB, Presta LG, Carter P. 1996. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9:617-621.
    • (1996) Protein Eng , vol.9 , pp. 617-621
    • Ridgway, J.B.1    Presta, L.G.2    Carter, P.3
  • 72
    • 77954674574 scopus 로고    scopus 로고
    • Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites
    • Bokemeyer C. 2010. Catumaxomab-trifunctional anti-EpCAM antibody used to treat malignant ascites. Expert Opin Biol Ther 10:1259-1269.
    • (2010) Expert Opin Biol Ther , vol.10 , pp. 1259-1269
    • Bokemeyer, C.1
  • 73
    • 84855586532 scopus 로고    scopus 로고
    • Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
    • Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D. 2012. Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 130:2195-2203.
    • (2012) Int J Cancer , vol.130 , pp. 2195-2203
    • Ott, M.G.1    Marmé, F.2    Moldenhauer, G.3    Lindhofer, H.4    Hennig, M.5    Spannagl, R.6    Essing, M.M.7    Linke, R.8    Seimetz, D.9
  • 83
    • 15244363849 scopus 로고    scopus 로고
    • T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro
    • Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG. 2005. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. Exp Hematol 33:452-459.
    • (2005) Exp Hematol , vol.33 , pp. 452-459
    • Gall, J.M.1    Davol, P.A.2    Grabert, R.C.3    Deaver, M.4    Lum, L.G.5
  • 87
    • 84922782339 scopus 로고    scopus 로고
    • Generation of a tetravalent bispecific antibody against IL4 and IL13 for the treatment of idiopathic pulmonary fibrosis
    • Rao E, Li D, Underwood S, Mikol V, Davison M, Kruip J. 2012. Generation of a tetravalent bispecific antibody against IL4 and IL13 for the treatment of idiopathic pulmonary fibrosis. MAbs 4:14-16.
    • (2012) MAbs , vol.4 , pp. 14-16
    • Rao, E.1    Li, D.2    Underwood, S.3    Mikol, V.4    Davison, M.5    Kruip, J.6
  • 92
    • 34547935736 scopus 로고    scopus 로고
    • Cell killing by antibody-drug conjugates
    • Kovtun YV, Goldmacher VS. 2007. Cell killing by antibody-drug conjugates. Cancer Lett 255:232-240.
    • (2007) Cancer Lett , vol.255 , pp. 232-240
    • Kovtun, Y.V.1    Goldmacher, V.S.2
  • 93
    • 84879591299 scopus 로고    scopus 로고
    • The antibody-drug conjugate: An enabling modality for natural product-based cancer therapeutics
    • Gerber HP, Koehn FE, Abraham RT. 2013. The antibody-drug conjugate: An enabling modality for natural product-based cancer therapeutics. Nat Prod Rep 30:625-639.
    • (2013) Nat Prod Rep , vol.30 , pp. 625-639
    • Gerber, H.P.1    Koehn, F.E.2    Abraham, R.T.3
  • 96
    • 84922832559 scopus 로고    scopus 로고
    • Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song F, DeGuzman MJ, Ensari S, Pinkstaff JK, Sullivan LM, Biroc SL, Cho H, Schultz PG, DiJoseph J, Dougher M
    • Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song F, DeGuzman MJ, Ensari S, Pinkstaff JK, Sullivan LM, Biroc SL, Cho H, Schultz PG, DiJoseph J, Dougher M,
  • 98
  • 100
    • 31544455876 scopus 로고    scopus 로고
    • Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
    • DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK. 2006. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma. Clin Cancer Res 12:242-249.
    • (2006) Clin Cancer Res , vol.12 , pp. 242-249
    • DiJoseph, J.F.1    Dougher, M.M.2    Kalyandrug, L.B.3    Armellino, D.C.4    Boghaert, E.R.5    Hamann, P.R.6    Moran, J.K.7    Damle, N.K.8
  • 102
    • 77950835018 scopus 로고    scopus 로고
    • Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer
    • Naumovski L, Junutula JR. 2010. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12:248-257.
    • (2010) Curr Opin Mol Ther , vol.12 , pp. 248-257
    • Naumovski, L.1    Junutula, J.R.2
  • 107
    • 84863470971 scopus 로고    scopus 로고
    • Marketing approval of mogamulizumab: A triumph for glyco-engineering
    • Beck A, Reichert JM. 2012. Marketing approval of mogamulizumab: A triumph for glyco-engineering. MAbs 4:419-425.
    • (2012) MAbs , vol.4 , pp. 419-425
    • Beck, A.1    Reichert, J.M.2
  • 108
    • 84906092974 scopus 로고    scopus 로고
    • Obinutuzumab: A new class of anti-CD20 monoclonal antibody
    • Gagez AL, Cartron G. 2014. Obinutuzumab: A new class of anti-CD20 monoclonal antibody. Curr Opin Oncol 26(5):484-491.
    • (2014) Curr Opin Oncol , vol.26 , Issue.5 , pp. 484-491
    • Gagez, A.L.1    Cartron, G.2
  • 112
    • 0035794194 scopus 로고    scopus 로고
    • High resolution mapping of the binding site on human IgG1 for FcRI, FcRII, FcRIII, and FcRn and design of IgG1 variants with improved binding to the FcR
    • Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. 2001. High resolution mapping of the binding site on human IgG1 for Fc(RI, Fc(RII, Fc(RIII, and FcRn and design of IgG1 variants with improved binding to the Fc(R. J Biol Chem 276:6591-6604.
    • (2001) J Biol Chem , vol.276 , pp. 6591-6604
    • Shields, R.L.1    Namenuk, A.K.2    Hong, K.3    Meng, Y.G.4    Rae, J.5    Briggs, J.6    Xie, D.7    Lai, J.8    Stadlen, A.9    Li, B.10    Fox, J.A.11    Presta, L.G.12
  • 114
    • 34548770705 scopus 로고    scopus 로고
    • Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors
    • Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S. 2007. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 67:8882-8890.
    • (2007) Cancer Res , vol.67 , pp. 8882-8890
    • Stavenhagen, J.B.1    Gorlatov, S.2    Tuaillon, N.3    Rankin, C.T.4    Li, H.5    Burke, S.6    Huang, L.7    Vijh, S.8    Johnson, S.9    Bonvini, E.10    Koenig, S.11
  • 118
    • 77953659426 scopus 로고    scopus 로고
    • Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
    • Moore GL, Chen H, Karki S, Lazar GA. 2010. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2:181-189.
    • (2010) MAbs , vol.2 , pp. 181-189
    • Moore, G.L.1    Chen, H.2    Karki, S.3    Lazar, G.A.4
  • 123
    • 84908218494 scopus 로고    scopus 로고
    • Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes
    • DEFEND Investigator Group.
    • Aronson R, Gottlieb PA, Christiansen JS, Donner TW, Bosi E, Bode BW, Pozzilli P; DEFEND Investigator Group. 2014. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: Results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 37:2746-2754.
    • (2014) Diabetes Care , vol.37 , pp. 2746-2754
    • Aronson, R.1    Gottlieb, P.A.2    Christiansen, J.S.3    Donner, T.W.4    Bosi, E.5    Bode, B.W.6    Pozzilli, P.7
  • 126
    • 33747631571 scopus 로고    scopus 로고
    • Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)
    • Dall'Acqua WF, Kiener PA, Wu H. 2006. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524.
    • (2006) J Biol Chem , vol.281 , pp. 23514-23524
    • Dall'Acqua, W.F.1    Kiener, P.A.2    Wu, H.3
  • 128
    • 0842264005 scopus 로고    scopus 로고
    • Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
    • Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC.2004. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 103:1472-1474.
    • (2004) Blood , vol.103 , pp. 1472-1474
    • Farag, S.S.1    Flinn, I.W.2    Modali, R.3    Lehman, T.A.4    Young, D.5    Byrd, J.C.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.